Search research articles
Contact Us
Filters
Showing results (31-40 of 56) with videos related to
Page
of 6
Sort By:
Haematologica
|
February 18, 2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Timothy P Hughes, Andreas Hochhaus, Hagop M Kantarjian, et al.
The Lancet. Haematology
|
December 22, 2015
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis
Jurjen Versluis, Carin L E Hazenberg, Jakob R Passweg, et al.
Blood
|
January 7, 2022
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
Gail J Roboz, Farhad Ravandi, Andrew H Wei, et al.
Haematologica
|
May 25, 2010
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial
Theo de Witte, Anne Hagemeijer, Stefan Suciu, et al.
Leukemia & Lymphoma
|
May 7, 2024
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study
Farhad Ravandi, Marion Subklewe, Roland B Walter, et al.
Blood
|
April 16, 2010
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome
Miguel A Sanz, Pau Montesinos, Chelo Rayón, et al.
Blood
|
November 6, 2024
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project
Maria Teresa Voso, Luca Guarnera, Söhren Lehmann, et al.
American Journal of Hematology
|
August 29, 2019
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
Michael Lauseker, Katharina Bachl, Anna Turkina, et al.
Journal of Visualized Experiments : Jove
|
March 20, 2018
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Jacqueline Cloos, Jeffrey R Harris, Jeroen J W M Janssen, et al.
Haematologica
|
March 26, 2026
Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy <i>versus</i> liposomal cytarabine and daunorubicin
Dimitrios Kotsos, Patrycja Gradowska, Sjoerd J F Hermans, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 56) with videos related to
Sort By:
Page
of 6
Haematologica
|
February 18, 2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Timothy P Hughes, Andreas Hochhaus, Hagop M Kantarjian, et al.
The Lancet. Haematology
|
December 22, 2015
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis
Jurjen Versluis, Carin L E Hazenberg, Jakob R Passweg, et al.
Blood
|
January 7, 2022
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
Gail J Roboz, Farhad Ravandi, Andrew H Wei, et al.
Haematologica
|
May 25, 2010
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial
Theo de Witte, Anne Hagemeijer, Stefan Suciu, et al.
Leukemia & Lymphoma
|
May 7, 2024
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study
Farhad Ravandi, Marion Subklewe, Roland B Walter, et al.
Blood
|
April 16, 2010
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome
Miguel A Sanz, Pau Montesinos, Chelo Rayón, et al.
Blood
|
November 6, 2024
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project
Maria Teresa Voso, Luca Guarnera, Söhren Lehmann, et al.
American Journal of Hematology
|
August 29, 2019
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin
Michael Lauseker, Katharina Bachl, Anna Turkina, et al.
Journal of Visualized Experiments : Jove
|
March 20, 2018
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Jacqueline Cloos, Jeffrey R Harris, Jeroen J W M Janssen, et al.
Haematologica
|
March 26, 2026
Treatment of therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes: a comparative analysis of higher-dose intensive 7+3 induction chemotherapy <i>versus</i> liposomal cytarabine and daunorubicin
Dimitrios Kotsos, Patrycja Gradowska, Sjoerd J F Hermans, et al.
Page
of 6